

Kontroversen zur fokalen Therapie des Prostatakarzinoms

Stefan Machtens

Literatur

1. Sanda MG et al. Quality of life and satisfaction with outcome among prostate cancer survivors. *N Engl J Med* 2008; 358: 1250–61
2. Resnick MJ et al. Long-term functional outcomes after treatment for localized prostate cancer. *N Engl J Med* 2013; 368: 436–45
3. Novara G et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. *Eur Urol* 2012; 62: 382–404
4. Schauer I et al. Have rates of erectile dysfunction improved within the past 17 years after radical prostatectomy? A systematic analysis of the control, arms of prospective randomized trials on penile rehabilitation. *Andrology* 2015; 3: 661–5
5. Zaorsky NG et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. *Cancer Treat Rev* 2016; 48: 50–60
6. Bokhorst LP et al. Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: active surveillance (PRIAS) study. *BJU Int* 2016; 118: 366–71
7. Leapman MS & Carroll PR. What is the best way not to treat prostate cancer? *Urol Oncol* 2017; 35: 42–50
8. Marzouk K et al. Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort. *J Urol* 2018; 200: 1250–5
9. Tan HJ et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. *J Urol* 2016; 195: 1724–30
10. Hoffmann RM et al. Treatment decision regret among long-term survivors of localized prostate cancer: results from the prostate cancer outcomes study. *J Clin Oncol* 2017; 35: 2306–14
11. Mcneal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. *Hum Pathol* 1992; 23: 258–66

12. Lin D et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen – identification of a small subpopulation with metastatic potential in the primary tumor. *Prostate* 2010; 70: 1636–44
13. Ahmed HU. The Index lesion and the origin of prostate cancer. *N Engl J Med* 2009; 361: 1704–6
14. Liu W et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Cancer* 2010; 165: 559–65
15. Onik G et al. Focal 'nerve-sparing' cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. *Urology* 2002; 60: 109–14
16. Ahmed HU et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. *Eur Urol* 2015; 68: 927–36
17. Eggener SE et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *J Urol* 2007; 178: 2260–7
18. Gill I et al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness. *J Urol* 2018; 200(4): 786–93
19. Valerio M et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. *Eur Urol* 2014; 66: 732–51
20. Langley S & Ahmed HU. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. *BJU Int* 2012; 109: 7–16
21. Tay KJ & Scheltma MJ. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi consensus project. *Prostate Cancer Prostatic Dis* 2017; 20: 294–9
22. S3-Leitlinie Prostatakarzinom; Leitlinienprogramm; Oktober 2021; Empfehlung 6.38
23. Isbarn H et al. Unilateral prostate cancer cannot be accurately predicted in low-risk patients. *Int J Radiat Oncol Biol Phys* 2010; 77: 784–7
24. Onik G et al. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2009; 27: 4321–6
25. de la Rosette J et al. Focal therapy in prostate cancer – report from a consensus panel. *J Endourol* 2010; 24: 775–80
26. Franiel T et al. (2015) Prostate Imaging--An Update. *Rofo* 2015; 187: 751–9
27. Franiel T et al. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. *Eur Radiol* 2011; 21: 616–26

28. Kasel-Seibert M et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. *Eur J Radiol* 2016; 85: 726–31
29. Franiel T et al. Prostate Imaging--An Update. *Rofo* 2015; 187: 751–9
30. Le JD et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. *Eur Urol* 2015; 67(3): 569–76
31. Kasivisvanathan V et al. MRI-targeted or standard biopsy for prostate cancer diagnosis. *N Eng J Med* 2018; 378; 1767–77
32. Piert M et al. Accuracy of tumor segmentation from multiparametric prostate MRI and (18) F-choline PET/CT for focal prostate cancer therapy application. *EJNMMI Res* 2018; 8: 23–8
33. Lopci E et al. 68 Ga-PSMA positron emission tomography / computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multi-parametric magnetic resonance imaging: A prospective observational study. *J Urol* 2018; 200: 95–103
34. Laader A et al. 1.5 versus 3 versus 7 Tesla in abdominal MRI: a comparative study. *PloS One* 2017; 12: e0187528
35. Ashrafi AN et al. Contrast-enhanced transrectal ultrasound in focal therapy for prostate cancer. *Curr Urol Rep* 2018; 19: 87–93
36. Scheltema MJ et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: a report from a Delphi consensus project. *World J Urol* 2017; 35(5): 695–701
37. Huber PM & Afzal N. Prostate Specific Antigen Criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. *J Urol* 2020; 203: 1–9
38. Ganzer R et al. Prospective multicenter phase II study on focal therapy (hemablation) of the prostate with high intensity focused ultrasound. *J Urol* 2018; 199: 983–9
39. Al Awamih BAH & Margolis DJ. (2020): Prostate multiparametric resonance imaging features following partial gland cryoablation. *Urology* 2020; 138: 98–105
40. Valerio M et al. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. *The Journal of Urology* 2017; 197: 647–54

41. Feijoo ER et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. *European Urology* 2016; 69: 214–20
42. Chin JL et al. Magnetic resonance-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: A prospective phase 1 clinical trial. *Eur Urol* 2016; 70: 447–55
43. Bonekamp D et al. Twelve Month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. *Eur Radiol* 2019; 29: 299–308
44. Lantz A et al. Prostate cancer IRE study (PRIS): a randomized controlled trial comparing focal therapy to radical treatment in localized prostate cancer. *Eur Urol Open Science* 2023; 51: 89–94
45. Aydin AM et al. Focal bipolar radiofrequency ablation for localized prostate cancer: safety and feasibility. *Int J Urol* 2020; 27: 882–9
46. Bass E et al. Intra-prostatic PRX302 focal therapy in treatment clinically significant low-intermediate prostate cancer: an open label, proof-of-concept study. *J Urol* 2017; 197: No4S, supplement
47. Rastinehad AR et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. *Proc Natl Acad Sci USA* 2019; 116: 18590–6
48. Yamada Y et al. Phase 1 study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol. *Contemp Clin Trials Commun* 2019; 16: 100471
49. Azzouzi AR et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol* 2017; 18(2): 181–91
50. Gill IS et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus Active Surveillance for low risk prostate cancer: extended follow-up and analyses of effectiveness. *J Urol* 2018; 200(4): 786–93
51. Herrero-Caceres JO et al. Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. *BJU Int* 2020; 125(4): 525–30
52. Pierrard V et al. Radical prostatectomy after vascular-targeted photodynamic therapy(VTP) with TOOKAD: feasibility, early and intermediate results. *J Urol* 2019; 201(2): 315–21